Viatris Rivaroxaban anticoagulant

Rivaroxaban Viatris is a generic anticoagulant medication used to prevent and treat blood clots. It contains the active substance rivaroxaban, which is a factor Xa inhibitor. The product is a generic version of the reference medicine Xarelto.

Viatris was formed in November 2020 through the merger of Mylan N.V. and Pfizer's Upjohn division. While the brand carries the Viatris name, its origins can be traced back to Mylan Laboratories, founded in 1961 in the United States, and the Upjohn Company, which dates back to 1886.

Manufacturing for Viatris products occurs across a vast global network. In Europe, the company operates major facilities in countries such as Ireland, France, Germany, and Italy. Specifically, many of their regional operations are managed via Viatris Limited (formerly Mylan) based in Dublin, Ireland. The company is currently a publicly traded entity headquartered in the United States.